icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon give very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C. Final results of the 4WIDUC study.
 
 
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
 
Øvrehus1, H. Krarup2 , I. Birkemose3, D. K. Holm4, B. Mössner1, P. B. Christensen1. 1Department of Infectious Diseases, Odense University Hospital, Denmark 2 Section of Molecular Diagnostics and Clinical Biochemistry, Aalborg University Hospital, Denmark, Drug Treatment Center, Odense Municipality, Denmark and 4Department of Clinical Immunology, Odense University Hospital, Denmark.

0426171

0426172

0426173

0426174

0426175

0426176

0426177

0426178